Skip to main content

Advertisement

SpringerLink
Log in

Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus

  • Original
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

Abstract

The objective of this study was to examine the effects of lovastatin on bone mineral density (BMD) of postmenopausal women with type 2 diabetes mellitus (DM). The study was an open-label clinical trial conducted from March 2002 to November 2003. Fifty-five postmenopausal women age 54–67 years with type 2 DM were allocated to lovastatin-treated and control (without lovastatin) groups based on low-density lipoprotein cholesterol (LDL-C) >130 or ≤130 mg/dl. The first group received lovastatin (20 mg daily titrated every 3 months to keep LDL-C less than 130 mg/dl) for a total of 18 months. The second group received their own diabetic regimen without statin. The BMD of the lumbar spine (L1-L4), femoral neck, Wards triangle, trochanter and total hip was measured by dual-energy X-ray absorptiometry at baseline and after 18 months. In the 28 women treated with lovastatin, the BMD increased in lumbar spine (from 0.946 (0.122) to 0.978 (0.135) g/cm2, p<0.01) and Ward’s triangle (from 0.685 (0.123) to 0.780 (0.186) g/cm2, p<0.01). In the 27 women not treated with statin, the changes in BMD at all bone sites were not statistically significant. BMD was higher in femoral neck (1.2% vs. −2.7%, p<0.05), Ward’s triangle (13.9% vs. 3.3%, p<0.05), trochanter (−0.1% vs. −2.9%, p<0.05), total hip (1.2% vs. −1.4%, p<0.05) and lumbar spine (3.4% vs. 1.2%, p>0.05) at the end of the study. Treatment with lovastatin may prevent bone loss in postmenopausal women with type 2 DM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anon (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646–650

    Google Scholar 

  2. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332:767–773

    Article  PubMed  CAS  Google Scholar 

  3. Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Cummings SR (1998) Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab 83:2239–2243

    Article  PubMed  CAS  Google Scholar 

  4. Slemenda C, Longcope C, Peacock M, Hui S, Johnston CC (1996) Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women. J Clin Invest 97:14–21

    Article  PubMed  CAS  Google Scholar 

  5. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB; Women’s Health Initiative Investigators (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290:1729–1738

    Article  PubMed  CAS  Google Scholar 

  6. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508–516

    Article  PubMed  CAS  Google Scholar 

  7. Riggs BL, Hartmann LC (2003) Selective estrogen-receptor modulators — mechanisms of action and application to clinical practice. N Engl J Med 348:618–629

    Article  PubMed  CAS  Google Scholar 

  8. Liao JK (2002) Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110:285–288

    Article  PubMed  CAS  Google Scholar 

  9. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946–1949

    Article  PubMed  CAS  Google Scholar 

  10. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, van der Klift M, Pols HA (2004) Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 164:146–152

    Article  PubMed  CAS  Google Scholar 

  11. Braatvedt GD, Bagg W, Gamble G, Davidson J, Reid IR (2004) The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes. Bone 35:766–770

    Article  PubMed  CAS  Google Scholar 

  12. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA (2000) HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 85:1137–1142

    Article  PubMed  CAS  Google Scholar 

  13. Nakashima A, Nakashima R, Ito T, Masaki T, Yorioka N (2004) HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus. Diabet Med 2:1020–1024

    Article  CAS  Google Scholar 

  14. Pedersen TR, Kjekshus J (2000) Statin drugs and the risk of fracture. 4S Study Group. JAMA 284:1921–1922

    Article  PubMed  CAS  Google Scholar 

  15. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe N (2001) Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 357:509–512

    Article  PubMed  CAS  Google Scholar 

  16. Wang PS, Solomon DH, Mogun H, Avorn J (2000) HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283:3211–3216

    Article  PubMed  CAS  Google Scholar 

  17. Whitfield JF (2001) Statins: new drugs for treating osteoporosis? Expert Opin Investig Drugs 10:409–415

    Article  PubMed  CAS  Google Scholar 

  18. Wakasugi M, Wakao R, Tawata M, Gan N, Koizumi K, Onaya T (1993) Bone mineral density measured by dual energy X-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus. Bone 14:29–33

    Article  PubMed  CAS  Google Scholar 

  19. van Daele PL, Stolk RP, Burger H, Algra D, Grobbee DE, Hofman A, Birkenhager JC, Pols HA (1995) Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study. Ann Intern Med 122:409–414

    PubMed  Google Scholar 

  20. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR (2001) Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 86:32–38

    Article  Google Scholar 

  21. Ivers RQ, Cumming RG, Mitchell P, Peduto AJ; Blue Mountains Eye Study (2001) Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care 24:1198–1203

    Article  PubMed  CAS  Google Scholar 

  22. Gregorio F, Cristallini S, Santeusanio F, Filipponi P, Fumelli P (1994) Osteopenia associated with non-insulin-dependent diabetes mellitus: what are the causes? Diabetes Res Clin Pract 23:43–54

    Article  PubMed  CAS  Google Scholar 

  23. Sosa M, Dominguez M, Navarro MC, Segarra MC, Hernandez D, de Pablos P, Betancor P (1996) Bone mineral metabolism is normal in non-insulin-dependent diabetes mellitus. J Diabetes Complications 10:201–205

    Article  PubMed  CAS  Google Scholar 

  24. Isaia GC, Ardissone P, Di Stefano M, Ferrari D, Martina V, Porta M, Tagliabue M, Molinatti GM (1999) Bone metabolism in type 2 diabetes mellitus. Acta Diabetol 36:35–38

    Article  PubMed  CAS  Google Scholar 

  25. Amayo AA, Kirera S (2004) Comparison of calculated and direct low density lipoprotein cholesterol determinations in a routine laboratory. East Afr Med J 81:154–158

    PubMed  CAS  Google Scholar 

  26. Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27:585–590

    Article  PubMed  CAS  Google Scholar 

  27. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R (2000) Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355:2185–2188

    Article  PubMed  CAS  Google Scholar 

  28. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283:3205–3210

    Article  PubMed  CAS  Google Scholar 

  29. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC (2002) Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 162:537–540

    Article  PubMed  CAS  Google Scholar 

  30. Sirola J, Sirola J, Honkanen R, Kroger H, Jurvelin JS, Maenpaa P, Saarikoski S (2002) Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women. Osteoporos Int 13:537–541

    Article  PubMed  CAS  Google Scholar 

  31. van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C (2001) Use of statins and risk of fractures. JAMA 285:1850–1855

    Article  PubMed  Google Scholar 

  32. Rejnmark L, Buus NH, Vestergaard P, Heickendorff L, Andreasen F, Larsen ML, Mosekilde L (2004) Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res 19:737–744

    Article  PubMed  CAS  Google Scholar 

  33. Wada Y, Nakamura Y, Koshiyama H (2000) Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med 160:2865

    Article  PubMed  CAS  Google Scholar 

  34. Grasser WA, Baumann AP, Petras SF, Harwood HJ Jr, Devalaraja R, Renkiewicz R, Baragi V, Thompson DD, Paraklar VM (2003) Regulation of osteoclast differentiation by statins. J Musculoskeletal Neuronal Interact 3:53–62

    CAS  Google Scholar 

  35. Inaba M, Nishizawa Y, Mita K, Kumeda Y, Emoto M, Kawagishi T, Ishimura E, Nakatsuka K, Shioi A, Morii H (1999) Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-dihydroxyvitamin D3 in patients with type 2 diabetes. Osteoporos Int 9:525–531

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Epidemiology and Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

    H. Safaei, M. Janghorbani, A. Aminorroaya & M. Amini

Authors
  1. H. Safaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Janghorbani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Aminorroaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Amini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Janghorbani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Safaei, H., Janghorbani, M., Aminorroaya, A. et al. Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus. Acta Diabetol 44, 76–82 (2007). https://doi.org/10.1007/s00592-007-0246-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-007-0246-6

Key words

Search

Navigation